AbbVie
Pays vs peer median
×1.36
+37% premium
Sample
51
high confidence
Last refreshed
2026-04-13
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×1.22 | 29 |
| neurology | ×1.50 | 5 |
| immunology | ×0.70 | 4 |
| gastroenterology | ×1.50 | 4 |
| dermatology | ×1.50 | 3 |
| ophthalmology | ×1.50 | 3 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| approved | ×1.49 | 12 |
| phase 1 | ×1.10 | 10 |
| phase 2 | ×1.50 | 9 |
| phase 3 | ×0.92 | 9 |
| preclinical | ×1.50 | 7 |
| discovery | ×0.87 | 4 |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2025 | CD38-tinib | BeiGene | HCC | approved | $3.0B | $15.9B |
| 2025 | Anti-RET-101 | ORIC Pharmaceuticals | AML | phase_3 | $786M | $4.1B |
| 2025 | mTOR-101 | Replimune | Follicular Lymphoma | discovery | $58M | $1.2B |
| 2025 | PD-1-201 | Zymeworks | T-cell Lymphoma | phase_3 | $602M | $4.9B |
| 2025 | In vivo CAR-T platform | Capstan Therapeutics | Lupus, Myasthenia Gravis | preclinical | $2.1B | $2.1B |
| 2025 | VEGFR | CRISPR Therapeutics | Endometrial | phase_3 | $820M | $5.8B |
| 2025 | B7-H4-201 | MacroGenics | Cholangiocarcinoma | preclinical | $53M | $481M |
| 2025 | Anti-BCMA-001 | Vor Biopharma | Pancreatic | phase_3 | $265M | $1.2B |
| 2025 | FLT3-301 | G1 Therapeutics | Colorectal | approved | $767M | $3.6B |
| 2025 | MUC1-101 | Nurix Therapeutics | Head & Neck | preclinical | $46M | $369M |
| 2025 | Anti-CD73-101 | Nkarta | DLBCL | phase_3 | $302M | $1.5B |
| 2025 | GPC3-201 | Ideaya Biosciences | Gastric | discovery | $15M | $279M |
| 2025 | Gubra obesity peptide | Gubra | Obesity | preclinical | $350M | $2.2B |
| 2024 | KRAS G12C-301 | Y-mAbs Therapeutics | Prostate | phase_1 | $149M | $1.7B |
| 2024 | mTOR-201 | Nektar Therapeutics | MPN | phase_3 | — | $678M |
How this is computed
For each AbbVie deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 51 disclosed deal premiums vs. peer medians. Raw premium 1.365, clamped to [0.7, 1.5].